Hepion Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

HEPA$0.11-13.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

Preferred Stock · Preferred Stock · Additional · Accumulated other · Total
Series A · Series C · Common Stock · Paid in · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2023	85,581	$855,808	1,688	$839,320	4,818,733	$482	$230,291,362	$(78,779)	$(224,627,386)	$7,280,807
Net loss	—	—	—	—	—	—	—	—	(2,853,806)	(2,853,806)
Other comprehensive income (loss)	—	—	—	—	—	—	—	87,979	—	87,979
Stock-based compensation expense	—	—	—	—	—	—	705,770	—	—	705,770
Warrant exercises, net	—	—	—	—	654,393	65	2,300,624	—	—	2,300,689
Balance at March 31, 2024	85,581	855,808	1,688	839,320	5,473,126	547	233,297,756	9,200	(227,481,192)	7,521,439
Net loss	—	—	—	—	—	—	—	—	(3,925,212)	(3,925,212)
Other comprehensive income (loss)	—	—	—	—	—	—	—	(63,022)	—	(63,022)
Stock-based compensation expense	—	—	—	—	—	—	28,625	—	—	28,625
Issuance of shares in abeyance	—	—	—	—	326,000	—	—	—	—	—
Balance at June 30, 2024	85,581	$855,808	1,688	$839,320	5,799,126	$547	$233,326,381	$(53,822)	$(231,406,404)	$3,561,830
Net loss	—	—	—	—	—	—	—	—	(4,865,948)	(4,865,948)
Other comprehensive income (loss)	—	—	—	—	—	—	—	(9)	—	(9)
Stock-based compensation expense	—	—	—	—	—	—	28,625	—	—	28,625
Issuance of common stock	—	—	—	—	1,159,245	116	868,701	—	—	868,817
Balance at September 30, 2024	85,581	$855,808	1,688	$839,320	6,958,371	$663	$234,223,707	$(53,831)	$(236,272,352)	$(406,685)

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Preferred Stock · Preferred Stock · Additional · Accumulated other · Total
Series A · Series C · Common Stock · Paid in · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2022	85,581	$855,808	1,801	$840,320	3,811,481	$381	$223,950,940	$(90,168)	$(175,701,344)	$49,855,937
Net loss	—	—	—	—	—	—	—	—	(13,259,921)	(13,259,921)
Other comprehensive income (loss)	—	—	—	—	—	—	—	19,353	—	19,353
Stock-based compensation expense	—	—	—	—	—	—	537,123	—	—	537,123
Conversion of Series C to common	—	—	(1)	(1,000)	1	—	1,000	—	—	—
Balance at March 31, 2023	85,581	855,808	1,800	839,320	3,811,482	381	224,489,063	(70,815)	(188,961,265)	37,152,492
Net loss	—	—	—	—	—	—	—	—	(14,079,547)	(14,079,547)
Other comprehensive income (loss)	—	—	—	—	—	—	—	(16,836)	—	(16,836)
Stock-based compensation expense	—	—	—	—	—	—	333,954	—	—	333,954
Stock-based liability awards converted to equity	—	—	—	—	—	—	2,983,006	—	—	2,983,006
Issuance of common stock in connection with stock split	—	—	—	—	26,807	3	(3)	—	—	—
Balance at June 30, 2023	85,581	$855,808	1,800	$839,320	3,838,289	$384	$227,806,020	$(87,651)	$(203,040,812)	$26,373,069
Net loss	—	—	—	—	—	—	—	—	(10,526,946)	(10,526,946)
Other comprehensive income (loss)	—	—	—	—	—	—	—	(6,277)	—	(6,277)
Stock-based compensation expense	—	—	—	—	—	—	318,911	—	—	318,911
Balance at September 30, 2023	85,581	$855,808	1,800	$839,320	3,838,289	$384	$228,124,931	$(93,928)	$(213,567,758)	$16,158,757

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.